Your browser doesn't support javascript.
loading
Pooled sequencing of 531 genes in inflammatory bowel disease identifies an associated rare variant in BTNL2 and implicates other immune related genes.
Prescott, Natalie J; Lehne, Benjamin; Stone, Kristina; Lee, James C; Taylor, Kirstin; Knight, Jo; Papouli, Efterpi; Mirza, Muddassar M; Simpson, Michael A; Spain, Sarah L; Lu, Grace; Fraternali, Franca; Bumpstead, Suzannah J; Gray, Emma; Amar, Ariella; Bye, Hannah; Green, Peter; Chung-Faye, Guy; Hayee, Bu'Hussain; Pollok, Richard; Satsangi, Jack; Parkes, Miles; Barrett, Jeffrey C; Mansfield, John C; Sanderson, Jeremy; Lewis, Cathryn M; Weale, Michael E; Schlitt, Thomas; Mathew, Christopher G.
Afiliación
  • Prescott NJ; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Lehne B; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom; Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom.
  • Stone K; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Lee JC; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Taylor K; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Knight J; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  • Papouli E; NIHR GSTFT/KCL Comprehensive Biomedical Research Centre Genomics Core Facility, King's College London School of Medicine, Guy's Hospital, London, United Kingdom.
  • Mirza MM; NIHR GSTFT/KCL Comprehensive Biomedical Research Centre Genomics Core Facility, King's College London School of Medicine, Guy's Hospital, London, United Kingdom.
  • Simpson MA; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Spain SL; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Lu G; Randall Division of Cell and Molecular Biophysics, King's College London, Guy's Campus, London, United Kingdom.
  • Fraternali F; Randall Division of Cell and Molecular Biophysics, King's College London, Guy's Campus, London, United Kingdom.
  • Bumpstead SJ; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom.
  • Gray E; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom.
  • Amar A; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Bye H; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Green P; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Chung-Faye G; Department of Gastroenterology, King's College Hospital NHS Foundation Trust, Denmark Hill, London, United Kingdom.
  • Hayee B; Department of Gastroenterology, King's College Hospital NHS Foundation Trust, Denmark Hill, London, United Kingdom.
  • Pollok R; Gastroenterology and Hepatology, St George's Healthcare NHS Trust, Tooting, London, United Kingdom.
  • Satsangi J; Gastrointestinal Unit, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom.
  • Parkes M; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Barrett JC; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom.
  • Mansfield JC; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Sanderson J; Guy's & St Thomas' NHS Foundation Trust, St Thomas' Hospital, Department of Gastroenterology, London, United Kingdom.
  • Lewis CM; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Weale ME; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Schlitt T; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom.
  • Mathew CG; Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom; Division of Medical Biochemistry, University of Cape Town, Cape Town, South Africa.
PLoS Genet ; 11(2): e1004955, 2015 Feb.
Article en En | MEDLINE | ID: mdl-25671699
The contribution of rare coding sequence variants to genetic susceptibility in complex disorders is an important but unresolved question. Most studies thus far have investigated a limited number of genes from regions which contain common disease associated variants. Here we investigate this in inflammatory bowel disease by sequencing the exons and proximal promoters of 531 genes selected from both genome-wide association studies and pathway analysis in pooled DNA panels from 474 cases of Crohn's disease and 480 controls. 80 variants with evidence of association in the sequencing experiment or with potential functional significance were selected for follow up genotyping in 6,507 IBD cases and 3,064 population controls. The top 5 disease associated variants were genotyped in an extension panel of 3,662 IBD cases and 3,639 controls, and tested for association in a combined analysis of 10,147 IBD cases and 7,008 controls. A rare coding variant p.G454C in the BTNL2 gene within the major histocompatibility complex was significantly associated with increased risk for IBD (p = 9.65x10-10, OR = 2.3[95% CI = 1.75-3.04]), but was independent of the known common associated CD and UC variants at this locus. Rare (<1%) and low frequency (1-5%) variants in 3 additional genes showed suggestive association (p<0.005) with either an increased risk (ARIH2 c.338-6C>T) or decreased risk (IL12B p.V298F, and NICN p.H191R) of IBD. These results provide additional insights into the involvement of the inhibition of T cell activation in the development of both sub-phenotypes of inflammatory bowel disease. We suggest that although rare coding variants may make a modest overall contribution to complex disease susceptibility, they can inform our understanding of the molecular pathways that contribute to pathogenesis.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicoproteínas de Membrana / Colitis Ulcerosa / Enfermedad de Crohn / Estudio de Asociación del Genoma Completo Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: PLoS Genet Asunto de la revista: GENETICA Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicoproteínas de Membrana / Colitis Ulcerosa / Enfermedad de Crohn / Estudio de Asociación del Genoma Completo Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: PLoS Genet Asunto de la revista: GENETICA Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos